On Saturday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...